| ID Source | ID |
|---|---|
| PubMed CID | 9571025 |
| CHEMBL ID | 307896 |
| MeSH ID | M0066754 |
| Synonym |
|---|
| norethisterone-3-oxime |
| CHEMBL307896 , |
| 23965-86-8 |
| unii-gg985xn6ck |
| 714964-42-8 |
| 19-norpregn-4-en-20-yn-3-one, 17-hydroxy-, oxime, (3e,17alpha)- |
| gg985xn6ck , |
| norethisterone oxime, (e)- |
| bdbm50217005 |
| (3e,8r,9s,10r,13s,14s,17r)-17-ethynyl-3-hydroxyimino-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol |
| 19-norpregn-4-en-20-yn-3-one, 17-hydroxy-, oxime, (3e,17.alpha.)- |
| Excerpt | Reference | Relevance |
|---|---|---|
| " No significant difference in pharmacokinetic parameters between the two drugs was observed." | ( [Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys]. Fu, GM; Li, DZ; Li, ZX; Wang, GP; Wang, XL; Wei, ZN; Zhao, XL; Zhou, MY; Zuo, MD, 1991) | 0.28 |
| " The pharmacokinetic parameters of the compounds were also compared." | ( [Pharmacokinetics of norethindrone-oxime and norethindrone in rabbits after oral administration]. Li, DZ; Liu, J; Pang, XB; Wang, GP; Zhao, XL; Zhou, MY, 1989) | 0.28 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Orally administered NETO was highly bioavailable (84." | ( Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. Hümpel, M; Li, QG, ) | 0.13 |
| " The absolute bioavailability for NETO and NET were found to be 64." | ( [Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys]. Fu, GM; Li, DZ; Li, ZX; Wang, GP; Wang, XL; Wei, ZN; Zhao, XL; Zhou, MY; Zuo, MD, 1991) | 0.28 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 5.8000 | 0.0005 | 1.8909 | 9.5000 | AID162967 |
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 5.8000 | 0.0650 | 3.1299 | 9.5000 | AID162967 |
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 5.8000 | 0.0260 | 3.5666 | 9.5000 | AID162967 |
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 5.8000 | 0.0210 | 3.5860 | 9.5000 | AID162967 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID162967 | In vitro inhibitory activity against pyruvate dehydrogenase kinase was determined | 1999 | Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15 | Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). |
| AID90951 | In vitro effective concentration in normal human dermal fibroblasts; No data | 1999 | Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15 | Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||